Yazar "Saygi, Haci Mehmet" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    Recurrent Intracranial Meningeal Hemangiopericytoma with an Isolated Bone Metastasis: A Case Report and Literature Review
    (Kare Publ, 2017) Turkkan, Gorkem; Caloglu, Murat; Usta, Ufuk; Yurut Caloglu, Vuslat; Saygi, Haci Mehmet; Uzal, Cem
    Intracranial meningeal hemangiopericytoma is a rare vascular tumor with a high rate of both local recurrence and the development of distant metastases. The aim of this report is to present the first case of recurrent meningeal hemangiopericytoma with an isolated femur metastasis and discuss the clinical features and treatment of this rare tumor. A 46-year-old woman was admitted with the complaint of sudden loss of consciousness and subsequently underwent an urgent craniotomy with total excision of the lesion. The diagnosis was meningeal hemangiopericytoma. The patient presented with a painful left hip 5 1/2 years after the initial surgery for the primary tumor. A lytic lesion, which was 4x4.5 cm in diameter, was seen on an X-ray of the proximal left femur. The patient underwent lesion removal surgery and pathological diagnosis was compatible with meningeal hemangiopericytoma. At 69th month, no progression has been observed in follow-up. Long-term follow-up is mandatory for meningeal hemangiopericytoma due to high recurrence rate many years after diagnosis. Further multi-institutional studies are strongly needed to understand the clinical behavior and treatment modalities of this rare disease.
  • Küçük Resim Yok
    Öğe
    Single-agent bevacizumab is an effective treatment in recurrent glioblastoma
    (Humana Press Inc, 2015) Hacibekiroglu, Ilhan; Kodaz, Hilmi; Erdogan, Bulent; Turkmen, Esma; Ozcelik, Melike; Esenkaya, Asim; Saygi, Haci Mehmet
    The aim of this study was to evaluate the efficiency and safety of single-agent bevacizumab therapy for recurrent glioblastoma multiforme (GBM). We identified patients with histologically confirmed glioblastoma and World Health Organization Grade III glioma who were previously treated with temozolomide plus radiotherapy and received 10 mg/kg bevacizumab intravenous infusion every 2 weeks until disease progression for recurrent disease. A total 24 patients included to this study. Twenty-two patients had GBM, and two patients had WHO grade III glioma. No complete response was observed, five patients (20.8 %) had partial response, nine patients (37.5 %) had stable diseases, and ten patients (41.7 %) had progressive diseases. The overall response rate was 20.8 %. The 6-month PFS rate (PFS6) and median PFS were determined as 37.5 % and 4.1 months, respectively. Median OS was 6.4 months. Performance status of 17 (70.8 %) patients was improved following bevacizumab regimen. Univariate analysis showed that improvement in performance status (IPS) following bevacizumab therapy was a significant predictor of both PFS (p < 0.001) and OS (p < 0.020). Bevacizumab-related adverse effects were observed in 13 (54.1 %) patients. Grade 3-4 toxicity was observed in 4 (16.6 %) patients. Therapy interruptions were experienced in two patients due to adverse effects. Single-agent bevacizumab is an effective and safe treatment alternative in recurrent GBM. IPS following bevacizumab therapy was a significant predictor of both PFS and OS.
  • Küçük Resim Yok
    Öğe
    Single-agent bevacizumab is an effective treatment in recurrent glioblastoma (vol 32, 12, 2015)
    (Humana Press Inc, 2015) Hacibekiroglu, Ilhan; Kodaz, Hilmi; Erdogan, Bulent; Turkmen, Esma; Ozcelik, Melike; Esenkaya, Asim; Saygi, Haci Mehmet
    [Abstract Not Available]